Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002666754 | SCV002972770 | uncertain significance | Maple syrup urine disease | 2022-08-12 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with alanine, which is neutral and non-polar, at codon 407 of the DBT protein (p.Thr407Ala). This variant is present in population databases (rs761825178, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with DBT-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002649955 | SCV003656577 | uncertain significance | Inborn genetic diseases | 2022-11-18 | criteria provided, single submitter | clinical testing | The c.1219A>G (p.T407A) alteration is located in exon 10 (coding exon 10) of the DBT gene. This alteration results from a A to G substitution at nucleotide position 1219, causing the threonine (T) at amino acid position 407 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Genome- |
RCV002666754 | SCV004050143 | uncertain significance | Maple syrup urine disease | 2023-04-11 | criteria provided, single submitter | clinical testing |